However, recent advancements in the classification of SCLC into four subtypes—based on transcription factor expression patterns and inflammation-related gene signatures—have opened new avenues for identifying patients who may derive greater benefit from PD-L1 inhibitors. The gene discussed is CD274; the disease is small cell lung carcinoma.